Should I Buy CATX? CATX 2026 Analysis

Should You Buy Perspective Therapeutics Inc (CATX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.710

1 Day change

1.73%

52 Week Range

6.160

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price is extended (RSI overbought) and sitting near resistance while a large discounted equity offering (priced at $3.79) is a near-term gravity point.
Near-term setup favors a pullback/mean reversion over chasing strength; risk-reward is unattractive at ~$5.1–$5.2 versus the fresh financing price.
Intellectia Proprietary Trading Signals
AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is positive and expanding (bullish momentum), but RSI(6)=82.18 signals overbought conditions and elevated pullback risk.
Moving averages: converging MAs suggest the trend is not cleanly established and can whipsaw after sharp moves.
Key levels: Pivot 3.993 is the main “line in the sand”; near resistance at R1=5.425 (current ~5.11–5.20 is close), with next resistance R2=6.31.
Interpretation: momentum is bullish, but the stock is technically stretched and close to resistance—poor timing for an impatient buy.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: OI put/call at 0.71 leans bullish (more calls than puts outstanding).
Flow: put volume is 0 with small total volume (27 calls), so “bullish” volume signal is weak due to low activity.
Volatility: IV 30d ~85.94 vs historical vol ~139.18; IV percentile ~3.6 (options relatively cheap vs recent history), often implying the market is not pricing imminent shock as aggressively as before.

Technical Summary

Sell

Buy

Positive Catalysts

- Competitive landscape tailwind: Sanofi’s deprioritization of Alphamedix reduces a perceived competitor (cited by H.C. Wainwright).
- Analyst support remains broadly constructive (multiple Buys) with targets well above spot.
- Pattern-based projection provided: similar-pattern basket suggests a positive 1-month bias (+5.73% expected move), though near-term is flat-to-negative.

Neutral/Negative Catalysts

- Dilution/overhang: large public offering priced at $3.79 (39.6M shares; ~$175M gross) is a major near-term headwind and can cap upside until absorbed.
- Technical stretch: RSI overbought increases probability of a near-term pullback.
- Competitive narrative risk remains (prior selloff tied to competitor data comparisons; UBS cited competition potentially impacting adoption).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $209K, down 43.36% YoY (top-line still minimal/volatile).
Profitability trend: Net loss improved to -$25.97M (71.73% YoY improvement); EPS improved to -$0.35 (66.67% YoY improvement) — cost/loss profile improving, but still firmly loss-making.
Overall: improving loss trajectory, but fundamentals remain development-stage and financing-driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent ratings skew positive (Buy/Outperform), but price targets have been volatile.
Upward move: H.C. Wainwright raised PT to $12 from $10 (Buy) on reduced competition.
Mixed/negative revisions: UBS cut PT sharply to $7 from $18 (kept Buy) on competition/commercial adoption concerns; Oppenheimer trimmed to $13 from $14 (Outperform) after competitive read-through.
Wall Street “pros”: strong enthusiasm for radiopharmaceutical platform and pipeline optionality; multiple firms maintain Buy-equivalent ratings.
Wall Street “cons”: competitive dynamics and commercialization uncertainty can swing sentiment sharply; targets have been cut materially by at least one major firm.

12 Analyst Rating

Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 11.82 USD with a low forecast of 4 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 4.630

Low

Averages

11.82

High

Current: 4.630

Low

Averages

11.82

High

H.C. Wainwright

Buy

upgrade

$10 -> $12

AI Analysis

2026-01-30

Reason

H.C. Wainwright

Price Target

$10 -> $12

AI Analysis

2026-01-30

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Perspective Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says Sanofi's deprioritization of Alphamedix eliminates a competitor for Perspective .

Truist

NULL -> Buy

initiated

$8 -> $12

2025-11-24

Reason

Truist

Price Target

$8 -> $12

2025-11-24

initiated

NULL -> Buy

Reason

Truist assumed coverage of Perspective Therapeutics with a Buy rating with a price target of $12, up from $8. The company is leading the next wave of radiopharmaceutical innovation, combining manufacturing readiness with cutting-edge molecular design to deliver precision oncology at scale, the analyst tells investors in a research note. Perspective's lead program VMT-alpha-NET has a promising interim phase 1/2B profile, and additional programs in melanoma and FAP offer upside, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CATX

Unlock Now

CATX Should I Buy

CATX Should I Buy

Should You Buy Perspective Therapeutics Inc (CATX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch